Repeated NT-proBNP testing and risk for adverse outcome after acute pulmonary embolism

 

^* Both authors contributed equally.

• References

• 1 Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178: 425-430.
• 2 ten Wolde M, Tulevski I I, Mulder JW. et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082-2084.
• 3 Kucher N, Printzen G, Doernhoefer et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1578.
• 4 Kostrubiec M, Pruszczyk P, Bochowicz A. et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26: 2166-2172.
• 5 Vuilleumier N, Perrier A, Sanchez JC. et al. Cardiac biomarkers levels predict pulmonary embolism extent on chest computed tomography and prognosis in non-massive pulmonary embolism. Thromb Haemost 2009; 101: 1176-1178.
• 6 Becattini C, Agnelli G. Predictors of mortality from pulmonary embolism and their influence on clinical management. Thromb Haemost 2008; 100: 747-751.
• 7 Agterof MJ, Schutgens RE, Snijder RJ. et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010; 8: 1235-1241.
• 8 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S-545S.
• 9 Kostrubiec M, Pruszczyk P, Kaczynska A. et al. Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. Clin Chim Acta 2007; 382: 124-128.